Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan

BACKGROUND: More than half of the patients selected based on KRAS mutation status fail to respond to the treatment with cetuximab in metastatic colorectal cancer (mCRC). We designed a study to identify additional biomarkers that could act as indicators for cetuximab treatment in mCRC. METHODS: We in...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seung Tae, Ahn, Tae Jin, Lee, Eunjin, Do, In-Gu, Lee, Su Jin, Park, Se Hoon, Park, Joon Oh, Park, Young Suk, Lim, Ho Yeong, Kang, Won Ki, Kim, Suk Hyeong, Lee, Jeeyun, Kim, Hee Cheol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4617450/
https://www.ncbi.nlm.nih.gov/pubmed/26486455
http://dx.doi.org/10.1186/s12885-015-1759-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4617450/
https://www.ncbi.nlm.nih.gov/pubmed/26486455
http://dx.doi.org/10.1186/s12885-015-1759-y

Ejemplares similares